illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. hospital & health care
  6. ›
  7. MaaT Pharma
Company logo

MaaT Pharma | Sustainability Performance

https://www.maatpharma.com
Linkedin

MaaT Pharma SA is involved in developing microbiome-based therapeutics. The company focuses on harnessing the gut microbiome to improve patient outcomes, particularly in cancer treatments and other health-related areas.

1923

France

51 - 200 employees

Biotechnology

$1M - 10M in revenue

N/A in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#10589
Overall
#486
in France
#222
in Biotechnology

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Beyond Top 100

Overview
Environmental
Digital emissions
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
Vetoquinol Global

France, Hospital & Health Care, Pharmaceuticals


Company logo
NextProtein

France, Hospital & Health Care, Biotechnology


Company logo
Union de Pharmacologie Scientifique Appliquee (UPSA)

France, Hospital & Health Care, Pharmaceuticals

Market cap

29.5M $, 2026▼103.1% YoY

Revenue

4.5M $, 2025▲25% YoY

R&D intensity

675% 2025

Digital Emissions


CO2e per visit (g)

Industry benchmark

B/M 0.26 g
1.49 g

D
Environmental ScoreScore D
Green HostingNo
Download Digital Emissions AnalysisPowered by illuminem and Dedalo AI

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • MaaT Pharma's microbiome-based therapeutics involve experimental treatments with uncertain safety profiles in clinical trials.
Powered by illuminem

Market cap

29.5M $, 2026▼103.1% YoY

Revenue

4.5M $, FY2025▲25% YoY

EBITDA

-38.4M $, FY2025▼9.1% YoY

Operating margin

-755% Industry: -370▼31.6% YoY

Revenue & EBITDA

$4.5MFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

-18.4M 2025▼39.6% YoY

Capex

0.0 2025▼NaN% YoY

Debt/equity ratio

9.7 Industry: 2▼NaN% YoY

R&D intensity

675.0%FY2025

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

-161.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

0.0

▼ 33.8%

2023

0.0

▼ 19.4%

2024

0.0

▼ 63.4%

2025

0.0

2029

Powered by illuminem

Sustainability targets and commitments

TargetYearValueScopeBaseline

Progress against targets

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Not available

Recycling policy

Not available

Workplace health & safety policy

Not available

27%
Independent Directors

4 out of 15 incl. management

Powered by illuminem

Overall score

0

Environment

0

Social

0

Governance

0

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Sustainability employees


Total sustainability employees

2-3


    Available in
    Scale package

    Access
  • Email

  • Email